Related Experiment Video
Updated: Jul 5, 2026

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells
Published on: June 20, 2018
Long-term effects of primary hypothyroidism on renal function in children
Aziz Elgadi1, Petra Verbovszki, Claude Marcus
1Department of Clinical Science, Intervention and Technology, Division of Pediatrics, Karolinska Institutet, Huddinge, Stockholm, Sweden. Aziz.Elgadi@klinvet.ki.se
Objectives:
To examine the impact of hypothyroidism on renal function in children and the effect of thyroid hormone therapy on the long-term outcome.
Study Design:
The glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were studied in 31 patients with symptomatic acquired hypothyroidism (age, 11 +/- 3.3 years) and in 50 healthy children (age, 10.5 +/- 4.5 years). Children with hypothyroidism were examined before starting thyroxine therapy and 1 week and 1, 3, and 6 months after starting thyroxine therapy. 13 patients were reinvestigated at 6, 12, 18, 36, and 60 months after initiating thyroxine therapy.
Results:
GFR and ERPF were <-2 SD of control levels in 58% and 45%, respectively, of children investigated before or within 1 week after starting thyroxine therapy. 31% and 6% of the children studied 1 to 6 months after thyroxine therapy had a GFR and ERPF <-2 SD. Moreover, when GFR and ERPF values were analyzed as percent of control mean, both measurements were reduced to an equal extent. At the last investigation, 1 to 5 years after start of treatment, the GFR was still significantly lower in children with hypothyroidism than that in control subjects.
Conclusion:
Acquired hypothyroidism during childhood may have a long-term impact on renal function.
Related Concept Videos
Hypothyroidism II: Pathophysiology
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Hyperthyroidism II: Pathophysiology
Chronic Kidney Disease II: Clinical Manifestations
Pharmacokinetics in Pediatric Patients: Drug Excretion
Acute Kidney Injury III: Clinical Manifestations
